Skip to main content
Journal cover image

Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor.

Publication ,  Journal Article
Lee, SY; Goh, BKP; Sadot, E; Rajeev, R; Balachandran, VP; Gönen, M; Kingham, TP; Allen, PJ; D'Angelica, MI; Jarnagin, WR; Coit, D; Wong, WK ...
Published in: Ann Surg Oncol
January 2017

BACKGROUND: The surgical management of duodenal gastrointestinal stromal tumors (DGIST) is poorly characterized. Limited resection may be technically feasible and oncologically safe, but anatomic considerations may compromise the resection margins due to the proximity of critical structures, thereby necessitating more extensive resections such as pancreaticoduodenectomy. METHODS: Patients undergoing surgery for DGIST at two institutions from 1994 to 2014 were identified. Clinicopathologic and survival data were analyzed to compare outcomes in patients treated with limited or radical resection. RESULTS: Sixty patients underwent surgery for DGIST. Pancreaticoduodenectomy was performed in 38 % while the rest underwent limited resections. The most common type of limited resection was wedge resection and primary closure (49 %) followed by segmental resection with an end-to-end or side-to-side duodenojejunostomy (27 %). The pancreaticoduodenectomy group tended to have larger tumors with the majority located in D2/3 (87 %) and at the mesenteric border (91 %). The pancreaticoduodenectomy group also had significantly greater intraoperative blood loss, longer operative time, longer hospital stay, and higher 90-day morbidity and readmission rates. The 5-year relapse-free survival, recurrence-free survival, and overall survival for the pancreaticoduodenectomy versus limited resection were 81 versus 56 % (p = 0.05), 64 versus 53 % (p = 0.5), and 76 versus 72 % (p = 0.6), respectively. A surgical algorithm based on the location and size of the tumor is proposed. CONCLUSIONS: Limited resection of DGIST is safe, but may be associated with lower 5-year relapse-free survival. Pancreaticoduodenectomy is recommended for selected patients with DGIST when an R0 resection cannot be performed without removing the ampulla or part of the pancreas.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

January 2017

Volume

24

Issue

1

Start / End Page

202 / 210

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Patient Readmission
  • Pancreaticoduodenectomy
  • Operative Time
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Length of Stay
  • Jejunostomy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, S. Y., Goh, B. K. P., Sadot, E., Rajeev, R., Balachandran, V. P., Gönen, M., … DeMatteo, R. P. (2017). Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol, 24(1), 202–210. https://doi.org/10.1245/s10434-016-5565-9
Lee, Ser Yee, Brian K. P. Goh, Eran Sadot, Rahul Rajeev, Vinod P. Balachandran, Mithat Gönen, T Peter Kingham, et al. “Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor.Ann Surg Oncol 24, no. 1 (January 2017): 202–10. https://doi.org/10.1245/s10434-016-5565-9.
Lee SY, Goh BKP, Sadot E, Rajeev R, Balachandran VP, Gönen M, et al. Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2017 Jan;24(1):202–10.
Lee, Ser Yee, et al. “Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor.Ann Surg Oncol, vol. 24, no. 1, Jan. 2017, pp. 202–10. Pubmed, doi:10.1245/s10434-016-5565-9.
Lee SY, Goh BKP, Sadot E, Rajeev R, Balachandran VP, Gönen M, Kingham TP, Allen PJ, D’Angelica MI, Jarnagin WR, Coit D, Wong WK, Ong HS, Chung AYF, DeMatteo RP. Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2017 Jan;24(1):202–210.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

January 2017

Volume

24

Issue

1

Start / End Page

202 / 210

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Patient Readmission
  • Pancreaticoduodenectomy
  • Operative Time
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Length of Stay
  • Jejunostomy